Clothes, towels, bedding, combs, and brushes, which came in contact with the infested individual, can be disinfected either by leaving them outside for at least two days or by washing them at 60 °C (140 °F) for 30 minutes. This is because adult lice can survive only one to two days without a blood meal and are highly dependent on human body warmth. Treatment
There are a number of treatments effective for head lice. These methods include combs, shaving, medical creams, and hot air. Medical creams usually require two treatments a week apart. Head lice are not justification to keep children home from school as the risk of spread is low. Mechanical measures
Wet combing (mechanical removal of lice through combing wet hair) can be used as treatment measure for those who are too young for pediculicide treatment, which is intended for 6 years of age or older. Wet combing a few times a day for a few weeks may also get rid of the infestation in half of people. This requires the use of a special lice comb with extra fine teeth. This is the recommended method for infants and women who are pregnant. Shaving the head can also effectively treat lice. Another treatment is the use of heated air applied by a hair dryer. This can be of special use in the early stages of an infestation, since it has very high mortality for eggs. Medications
There are many medications which can kill lice.
On behalf of the NCI, they were awarded patents on these activities. Since the NCI does not market products directly, the National Institutes of Health (NIH) awarded a ten-year exclusive license to Bristol-Myers Squibb Co. (BMS) to market and sell ddI as Videx tablets. Didanosine became the second drug approved for the treatment of HIV infection in many other countries, including in the United States by the Food and Drug Administration (FDA) on October 9, 1991. Its FDA approval helped bring down the price of zidovudine (ZDV), the initial anti-HIV drug. [Source needed on pricing effect.] Didanosine has weak acid stability and is easily damaged by stomach acid. Therefore, the original formula approved by the FDA used chewable tablets that included an antacid buffering compound to neutralize stomach acid. The chewable tablets were not only large and fragile, they also were foul-tasting and the buffering compound would cause diarrhea. Although the FDA had not approved the original formulation for once-a-day dosing it was possible for some people to take it that way. At the end of its ten-year license, BMS re-formulated Videx as Videx EC and patented that, which reformulation the FDA approved in 2000. The new formulation is a smaller capsule containing coated microspheres instead of using a buffering compound. It is approved by the FDA for once-a-day dosing. Also at the end of that ten-year period, the NIH licensed didanosine to Barr Laboratories under a non-exclusive license, and didanosine became the first generic anti-HIV drug marketed in the United States.